CSIMarket Company Name, Ticker, Industry, else..
 
Lixte Biotechnology Holdings Inc   (NASDAQ: LIXT)
Other Ticker:  
 
 
Price: $1.2200 $-0.13 -9.630%
Day's High: $1.3394 Week Perf: -6.87 %
Day's Low: $ 1.21 30 Day Perf: -19.88 %
Volume (M): 32 52 Wk High: $ 3.87
Volume (M$): $ 40 52 Wk Avg: $2.16
Open: $1.28 52 Wk Low: $1.02



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 2
 Employees 12
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings Inc is a biopharmaceutical company based in East Setauket, New York. It focuses on developing novel drugs for the treatment of various cancers. The company's primary focus is on developing inhibitors of protein phosphatases, which are involved in regulating critical signaling pathways in cancer cells. Lixte Biotechnology aims to identify and develop targeted therapies that can potentially improve the outcomes of cancer patients. The company's research and development efforts primarily involve preclinical studies and early-stage clinical trials to evaluate the safety and efficacy of its drug candidates.


   Company Address: 680 East Colorado Boulevard Pasadena 91101 CA
   Company Phone Number: 830-7092   Stock Exchange / Ticker: NASDAQ LIXT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BPMC        2.54% 
MEIP        0.43% 
RIGL   -3.09%    
RYTM        3.8% 
SUPN        0.03% 
WVE        3.23% 
• View Complete Report
   



Lixte Biotechnology Holdings Inc

LIXT Biotechnology Holdings Inc. Faces Operating Shortfall in Fourth Quarter of 2023, Sees Improvement on Bottom-line

Lixte Biotechnology Holdings Inc, a company in the Major Pharmaceutical Preparations sector, recently reported its financial results for the fourth quarter of 2023. The company experienced an operating shortfall of $-1.02591 million during this period and did not generate any revenue. This is a significant decline in productivity compared to the same quarter in 2022.
Lixte Biotechnology Holdings Inc is primarily in the development stage, which is an important factor to consider when interpreting its financial results. Despite the operating shortfall, there has been some improvement on the bottom-line, with the deficit decreasing from $-1.631 million in Q4 2022 to $-1.032 million in Q4 2023.
Lixte Biotechnology Holdings Inc

Lixte Biotechnology Holdings Inc. Faces Setback with Operating Loss in Q3 2023



Pharmaceutical preparations sector advisors have started analyzing the financial performance of Lixte Biotechnology Holdings Inc for the third quarter of 2023. Despite the company not reporting any top-line figures yet, there are positive signs to signify progress. This article will outline the key facts and interpret the financial results, providing investors with a clearer understanding of Lixte Biotechnology's current standing.
Operating Loss:
Lixte Biotechnology Holdings Inc recorded an operating loss of $-1.024181 million in the third quarter of 2023. While the absence of top-line figures is noteworthy, the operating loss shows improvement compared to the same quarter in 2022, which reported a loss of $-1.478501 million. This reduction in operating loss signals positive growth and has given investors affirmation about Lixte Biotechnology's potential.
Lixte Biotechnology Holdings Inc

Lixte Biotechnology Holdings Inc Reports Operating Loss of $-1.67 million in Financial Quarter Ending Jun 30, 2023



Lixte Biotechnology Holdings Inc, a major player in the pharmaceutical preparations sector, recently released its second-quarter financial numbers. As industry insiders analyze the figures, concerns arise surrounding the company's dismal performance. The absence of a specified top-line for the April to June 2023 quarter is a glaring issue, giving rise to speculation about the company's financial struggles. This article aims to delve into the financial woes faced by Lixte Biotechnology Holdings Inc, highlighting their growing operating loss and a concerning shortfall compared to the previous year.
Operating Loss Amplifies:
Lixte Biotechnology Holdings Inc's second-quarter analysis reveals a distressing operating loss of $-1.669998 million. Yet, the company fails to provide any information regarding its top-line during this period. This omission raises concerns about the company's ability to generate revenue and meet financial obligations. It is surprising that a rising player in the industry, with apparent growth potential, has not been forthcoming with its financial performance.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com